 |
市場調查報告書
商品編碼
2008061
福萊德瑞克運動失調症(FA) 市場：按藥物類別、給藥途徑、分銷管道和地區分類Friedreich's Ataxia Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography |
||||||
價格
簡介目錄
2026年福萊德瑞克運動失調症（FA）市場規模估計為7.935億美元，預計到2033年將達到15.131億美元。預計從2026年到2033年，其複合年成長率將達到10.5%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 7.935億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 10.50% | 2033年市場規模預測： | 15.131億美元 |
共濟失調是指一系列影響大腦協調和運動中樞（小腦）的神經退化性疾病。共濟失調患者會出現吞嚥困難、言語障礙、平衡和協調能力下降。共濟失調有多種類型，包括脊髓小腦變性、福萊德瑞克運動失調症（FA）、毛細血管擴張性共濟失調、多重系統退化症症（MSA）和陣發性共濟失調。福萊德瑞克運動失調症（FA）可發生於任何年齡，且是一種進行性疾病，這意味著症狀會隨著時間推移而加重。福萊德瑞克運動失調症（FA）是一種遺傳性疾病，由缺陷基因引起，導致FA代代相傳。除了常見的運動相關症狀外，福萊德瑞克運動失調症（FA）患者還會出現肌肉僵硬和感覺喪失、全身肌肉無力以及心臟疾病（肥厚型心肌病病變）等症狀。
市場動態
預計在預測期內，福萊德瑞克運動失調症（FA）市場成長的主要驅動力將是：福萊德瑞克運動失調症（FA）患者數量眾多、技術進步以及市場主要企業擴大採用收購、合併和合作等非內部成長戰略。
例如，根據 2022 年 2 月發表在同行評審開放獲取科學期刊《神經科學前沿》上的一篇評論文章，截至 2021 年，弗里德賴希型共濟失調的患病率估計為全球整體每 50,000 人中 1 人。
此外，2019 年 2 月，英國牛津大學和美國俄亥俄州一家大學醫院的哈靈頓發現研究所宣佈建立全球合作夥伴關係，以解決患有肌肉萎縮症萎縮症、囊腫纖維化和共濟失調等罕見疾病的患者未被滿足的需求。
本次調查的主要特點。
- 本報告對全球福萊德瑞克運動失調症（FA）市場進行了詳細分析，以 2021 年為基準年，給出了預測期（2022-2030 年）的市場規模和復合年成長率。
- 本報告指出了各個細分市場的潛在商機，並說明了該市場中具有吸引力的投資提案矩陣。
- 此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
- 本報告根據以下參數，介紹了全球福萊德瑞克運動失調症(FA) 市場的主要企業概況：公司概況、財務業績、產品系列、市場地位、分銷策略、主要發展、戰略和未來計劃。
- 透過利用本報告中提出的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
- 本報告面向該產業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 透過對全球福萊德瑞克運動失調症（FA）市場進行分析時所使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。
目錄
第1章：研究目標與前提條件
- 研究目標
- 前提
- 簡稱
第2章 市場範圍
- 報告摘要
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 阻礙因素
- 市場機遇
- 影響分析
- 市場趨勢
- 主要進展
- 產品核准
- 合作關係、併購
- 監理情勢
- PEST分析
- 波特五力分析
- 流行病學
- 強大的管道分析
第4章：福萊德瑞克運動失調症（FA）市場：按藥物類別分類，2026-2033年
- ACE抑制劑
- BETA受體阻斷劑
- 利尿劑
- 對苯醌
- 其他（維生素E、免疫調節劑、骨骼肌鬆弛劑、抗癲癇藥物等）
第5章：福萊德瑞克運動失調症（FA）市場：依給藥途徑分類，2026-2033年
- 口服
- 注射
第6章：福萊德瑞克運動失調症（FA）市場：依分銷管道分類，2026-2033年
- 醫院藥房
- 零售藥房
- 網路藥房
第7章：福萊德瑞克運動失調症（FA）市場：按地區分類，2026-2033年
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 亞太其他地區
- 中東
- GCC
- 以色列
- 其他中東國家
- 非洲
- 北非
- 中非
- 南非
第8章 競爭情勢
- 熱圖分析
- 市佔率分析
- 公司簡介
- Reata Pharmaceuticals, Inc.
- Retrotope Inc.
- Minoryx
- PTC Therapeutics
- Design Therapeutics, Inc.
- Larimar Therapeutics, Inc.
- Jupiter Neurosciences, Inc.
- Lexeo Therapeutics
- Zydus Lifesciences Ltd.
- Cipla Limited
- GlaxoSmithKline Plc.
- Aurobindo Pharma Ltd.
- Sun Pharmaceutical Industries Ltd.
- Torrent Pharmaceuticals Ltd.
- Intas Pharmaceuticals Ltd.
第9章
- 參考
- 調查方法
- 關於本公司
簡介目錄
Product Code: CMI5034
Friedreich's Ataxia Market, is estimated to be valued at USD 793.5 Mn in 2026 and is expected to reach USD 1,513.1 Mn by 2033, growing at a compound annual growth rate (CAGR) of 10.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 793.5 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 10.50% | 2033 Value Projection: | USD 1,513.1 Mn |
Ataxia refers to a group of degenerative neurological diseases that affect coordination and movement center of the brain (cerebellum). People suffering from ataxia have difficulty in swallowing, speech, and maintaining balance or coordination. Ataxia can be of several types such as spinocerebellar ataxia, Friedreich's ataxia, ataxia-telangiectasia, multiple system atrophy (MSA), episodic ataxia, and others. Friedreich's ataxia can develop at any age and is progressive in nature i.e. it worsens with time. Friedreich's ataxia (FA) is a genetic ataxia that is caused when a damaged gene which leads to FA is passed from one generation to the other. In addition to common movement related symptoms, people suffering from Friedreich's ataxia also experience symptoms such as stiffness and loss of sensation in muscles, weakness in the body, heart condition (hypertrophic cardiomyopathy), and others.
Market Dynamics
High burden of Friedreich's ataxia, rising technological advancements, and increasing adoption of inorganic growth strategies such as acquisitions, mergers, and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global Friedreich's ataxia market over the forecast period.
For instance, according to a review article published by the Frontiers in Neuroscience journal, a peer-reviewed open access scientific journal, in February 2022, it was estimated that the prevalence of Friedreich ataxia was 1:50,000 individuals, around the globe as of 2021
Moreover, in February 2019, the University of Oxford, England and Harrington Discovery Institute at University Hospitals in Ohio, U.S. announced a global partnership to address unmet need of patients suffering from rare diseases such as muscular dystrophy, cystic fibrosis, ataxia, and others
Key features of the study
- This report provides an in-depth analysis of the global Friedreich's ataxia market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new Material launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global Friedreich's ataxia market based on the following parameters - company overview, financial performance, Material portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Reata Pharmaceuticals, Inc., Retrotope Inc., Minoryx, PTC Therapeutics, Design Therapeutics, Inc., Larimar Therapeutics, Inc., Jupiter Neurosciences, Inc., Lexeo Therapeutics, Zydus Lifesciences Ltd., Cipla Limited, GlaxoSmithKline Plc., Aurobindo Pharma Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Intas Pharmaceuticals Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future Material launches, type up-gradation, market expansion, and marketing tactics
- The global Friedreich's ataxia market report caters to various stakeholders in this industry including investors, suppliers, Material manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Friedreich's ataxia market
Market Segmentation
- By Drug Class
- ACE Inhibitors
- Beta Blockers
- Diuretics
- Para-Benzoquinone
- Others (Vitamin E, Immunomodulators, Skeletal Muscle Relaxants, and Anti-Epileptic Drugs, among others)
- By Route of Administration
- Oral
- Injectable
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Key Players
- Reata Pharmaceuticals, Inc.
- Retrotope Inc.
- Minoryx
- PTC Therapeutics
- Design Therapeutics, Inc.
- Larimar Therapeutics, Inc.
- Jupiter Neurosciences, Inc.
- Lexeo Therapeutics
- Zydus Lifesciences Ltd.
- Cipla Limited
- GlaxoSmithKline Plc.
- Aurobindo Pharma Ltd.
- Sun Pharmaceutical Industries Ltd.
- Torrent Pharmaceuticals Ltd.
- Intas Pharmaceuticals Ltd
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Friedreich's Ataxia Market, By Drug Class, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026- 2033
- Segment Trends
- ACE Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Beta Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Diuretics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Para-Benzoquinone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Others (Vitamin E, Immunomodulators, Skeletal Muscle Relaxants, and Anti-Epileptic Drugs, among others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
5. Friedreich's Ataxia Market, By Route of Administration, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
6. Friedreich's Ataxia Market, By Distribution Channel, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
7. Friedreich's Ataxia Market, By Region, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2026-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 - 2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- Reata Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Retrotope Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Minoryx
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- PTC Therapeutics
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Design Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Larimar Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Jupiter Neurosciences, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Lexeo Therapeutics
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Zydus Lifesciences Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Cipla Limited
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- GlaxoSmithKline Plc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Aurobindo Pharma Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Torrent Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Intas Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Analyst Views
9. Section
- References
- Research Methodology
- About Us
